The 90-day pause on most of President Trump’s planned tariffs may have had a somewhat stabilizing effect on the stock market, but there is still significant volatility for the biopharma sector as the possibility of sector-specific tariffs on pharmaceuticals looms. Biotech firms are in a precarious position not just because of the potential impacts of tariffs, but due to the wider effects on capital markets.
Key Takeaways
- The 90-day pause on the Trump administration’s tariffs brought some relief, but both small and large biopharma firms are preparing for the possibility of pharmaceutical-focused tariffs.
- Smaller companies are assessing their domestic versus off-shore manufacturing processes and how they can adjust to limit the impact of tariffs
Pre-commercial biotech companies may face less exposure to tariff policies than big commercial companies, but the smaller firms are also more vulnerable to setbacks, as they have less diversification and more financial pressure. Between the implications for supply chains, the stock market downturn and the ramifications for capital markets, startup and pre-commercial firms are facing a crunch. Adding to that are the recent layoffs at the US Food and Drug Administration – more than 200 biotech and investors
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?